EP1148877A4 - Verfahren zur hemmung der knochenresorption - Google Patents

Verfahren zur hemmung der knochenresorption

Info

Publication number
EP1148877A4
EP1148877A4 EP99970321A EP99970321A EP1148877A4 EP 1148877 A4 EP1148877 A4 EP 1148877A4 EP 99970321 A EP99970321 A EP 99970321A EP 99970321 A EP99970321 A EP 99970321A EP 1148877 A4 EP1148877 A4 EP 1148877A4
Authority
EP
European Patent Office
Prior art keywords
methods
bone resorption
inhibiting bone
inhibiting
resorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99970321A
Other languages
English (en)
French (fr)
Other versions
EP1148877A1 (de
Inventor
Shun-Ichi Harada
Mohamed Machwate
Gideon A Rodan
Marc Labelle
Kathleen Metters
Robert N Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Merck and Co Inc
Original Assignee
Merck Frosst Canada and Co
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9824572.3A external-priority patent/GB9824572D0/en
Application filed by Merck Frosst Canada and Co, Merck and Co Inc filed Critical Merck Frosst Canada and Co
Publication of EP1148877A1 publication Critical patent/EP1148877A1/de
Publication of EP1148877A4 publication Critical patent/EP1148877A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP99970321A 1998-10-15 1999-10-12 Verfahren zur hemmung der knochenresorption Withdrawn EP1148877A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10433998P 1998-10-15 1998-10-15
US104339P 1998-10-15
GB9824572 1998-11-09
GBGB9824572.3A GB9824572D0 (en) 1998-11-09 1998-11-09 Methods for inhibiting bone resorption
PCT/US1999/023616 WO2000021532A1 (en) 1998-10-15 1999-10-12 Methods for inhibiting bone resorption

Publications (2)

Publication Number Publication Date
EP1148877A1 EP1148877A1 (de) 2001-10-31
EP1148877A4 true EP1148877A4 (de) 2003-01-22

Family

ID=26314644

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99970321A Withdrawn EP1148877A4 (de) 1998-10-15 1999-10-12 Verfahren zur hemmung der knochenresorption

Country Status (5)

Country Link
EP (1) EP1148877A4 (de)
JP (1) JP2002527393A (de)
AU (1) AU1444200A (de)
CA (1) CA2346038A1 (de)
WO (1) WO2000021532A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
EE200200355A (et) * 1999-12-22 2003-10-15 Pfizer Products Inc. EP4 retseptori selektiivsed agonistid osteoporoosi raviks
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
DE60130675T2 (de) 2000-11-27 2008-01-24 Pfizer Products Inc., Groton Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
CA2451392A1 (en) 2001-07-16 2003-01-30 F. Hoffmann-La Roche Ag Prostaglandin analogues as ep4 receptor agonists
EP1408961B1 (de) 2001-07-16 2007-07-11 F. Hoffmann-La Roche Ag 2 pyrrolidon-derivate als prostanoid-agonisten
KR100826866B1 (ko) 2001-07-23 2008-05-06 오노 야꾸힝 고교 가부시키가이샤 Ｅｐ４ 아고니스트를 유효 성분으로 하는 골량 저하질환의 치료제
EP1467738A1 (de) * 2001-10-08 2004-10-20 Medical Research Council Verwendung von prostaglandin e synthase inhibitoren, oder ep2/ep4 rezeptor antagonisten, zur behandlung von uterine krankheiten
JP2006515015A (ja) 2003-01-10 2006-05-18 エフ．ホフマン−ラ　ロシュ　アーゲー プロスタグランジンアゴニストとしての２−ピペリドン誘導体
US7179820B2 (en) 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
BRPI0720254A2 (pt) 2006-12-15 2014-01-07 Glaxo Group Ltd Derivados de benzamida como agonistas do receptor ep4
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
EP2392323A4 (de) 2009-01-30 2012-09-26 Univ Kyoto Progressionshemmer für prostatakrebs und verfahren zur progressionshemmung
EP2846793A1 (de) 2012-05-09 2015-03-18 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und pharmazeutische zusammensetzungen zur vorbeugung oder behandlung von chronisch obstruktiver lungenerkrankung

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526001A1 (de) * 1991-07-03 1993-02-03 Merck & Co. Inc. Substituierte Triazolinone

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411980A (en) * 1989-07-28 1995-05-02 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526001A1 (de) * 1991-07-03 1993-02-03 Merck & Co. Inc. Substituierte Triazolinone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0021532A1 *

Also Published As

Publication number Publication date
JP2002527393A (ja) 2002-08-27
CA2346038A1 (en) 2000-04-20
AU1444200A (en) 2000-05-01
EP1148877A1 (de) 2001-10-31
WO2000021532A1 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
EP1088333A4 (de) Verfahren und zussamensetzungen zur verbindung von osteoprose
HUP0104836A3 (en) Bone fixation system
HK1021499A1 (en) A surgical system for dermablation
IL133775A0 (en) Method for providing refrigeration
IL118196A0 (en) Methods for inhibiting bone loss
AU3359697A (en) Bone resorption inhibitors
GB9812103D0 (en) Surgical implant
EP1148877A4 (de) Verfahren zur hemmung der knochenresorption
GB9819243D0 (en) Method for inhibiting bone resorption
EP1089750A4 (de) Zusammensetzungen und verfahren zur inhibierung von knochenresorption.
GB9824572D0 (en) Methods for inhibiting bone resorption
EP1142579A4 (de) Hemmstoffe der knochenresorption
AU137972S (en) Implant
GB9809791D0 (en) Methods of inhibiting bone resorption
GB9810885D0 (en) Methods of inhibiting bone resorption
GB9822699D0 (en) Methods of inhibiting bone resorption
GB9819126D0 (en) Compositions and methods for inhibiting bone resorption
GB9822330D0 (en) Compositions and methods for inhibiting bone resorption
GB9817170D0 (en) Compositions and methods for inhibiting bone resorption
AU741818C (en) Method for inhibiting bone resorption
GB9826207D0 (en) Bone conditions
GB9821388D0 (en) Spinal implants
GB9824574D0 (en) Methods for regulating bone formation
HU9801479D0 (en) Mechanical tachitoscope for improving fixation width
HU9800093V0 (en) Skate-board for field

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010515

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010515;LT PAYMENT 20010515;LV PAYMENT 20010515;MK PAYMENT 20010515;RO PAYMENT 20010515;SI PAYMENT 20010515

A4 Supplementary search report drawn up and despatched

Effective date: 20021205

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030522

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040309